Methods: We retrospectively identified all cases associated with Acinetobacter clinical isolates in the Barnes-Jewish/Children’s Hospital system (St. Louis, MO) from 2007-2017. First isolates were classified as AcbC or non-AcbC. Tissue of origin, hospital-day of isolation, and antibiotic resistance profiles were determined. Results were compared to an ongoing prospective analysis of Acinetobacter isolates in the same system, started in July 2017.
Results: We identified 2959 and 1243 cases associated with AcbC and non-AcbC isolates, respectively. In both groups, isolates were most commonly obtained from respiratory (34% and 30% of total isolates) and connective tissue (34% and 27% of total isolates) sites. Urinary tract specimens were more likely to occur among AcbC isolates compared to non-AcBC isolates (664/2959 [22%] vs 147/1243 [12%], p<0.001). The percentage of isolates obtained prior to hospital-day-2 are 62% and 78% for AcbC and non-AcbC isolates, respectively. AcbC isolates were markedly more resistant to all classes of antibiotics. Analysis of 77 AcbC and 58 non-AcbC prospectively collected isolates revealed similar clinical findings.
Conclusion: Our study confirms the protean nature of Acinetobacter clinical isolates, and begins to describe relevant differences between AcbC and non-AcbC strains. These distinctions support the practice of identifying clinical isolates using AcbC and non-AcbC labels. Ongoing studies will further describe the patient characteristics and clinical outcomes associated with Acinetobacter disease in our system.
J. Calix Jr.,
M. Feldman, None
See more of: Poster Abstract Session